Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 4
1998 1
1999 2
2000 1
2001 1
2003 1
2006 1
2008 1
2011 1
2015 1
2017 1
2018 1
2019 1
2020 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Butenafine.
[No authors listed] [No authors listed] 2018 Oct 31. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2018 Oct 31. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 30000508 Free Books & Documents. Review.
Topical butenafine has not been studied during breastfeeding. Because it is poorly absorbed after topical application, it is not likely to reach the bloodstream of the infant or cause any adverse effects in breastfed infants. ...
Topical butenafine has not been studied during breastfeeding. Because it is poorly absorbed after topical application, it is not like …
Butenafine.
McNeely W, Spencer CM. McNeely W, et al. Drugs. 1998 Mar;55(3):405-12; discussion 413. doi: 10.2165/00003495-199855030-00006. Drugs. 1998. PMID: 9530545 Review.
Butenafine is a new antifungal agent with primary fungicidal activity against dermatophytes such as Trichophyton mentagrophytes, Microsporum canis and Trichophyton rubrum which cause tinea infections. 14C-labelled butenafine (approximately 30 micrograms/g tissue) wa …
Butenafine is a new antifungal agent with primary fungicidal activity against dermatophytes such as Trichophyton mentagrophytes, Micr …
Butenafine and superficial mycoses: current status.
Singal A. Singal A. Expert Opin Drug Metab Toxicol. 2008 Jul;4(7):999-1005. doi: 10.1517/17425255.4.7.999. Expert Opin Drug Metab Toxicol. 2008. PMID: 18624686 Review.
BACKGROUND: Butenafine hydrochloride, a benzylamine derivative, exhibits potent fungicidal activity particularly against dermatophytes, aspergilli, dimorphic and dematiaceous fungi. OBJECTIVE: To review pharmacokinetics, mechanism of actions and clinical efficacy of but …
BACKGROUND: Butenafine hydrochloride, a benzylamine derivative, exhibits potent fungicidal activity particularly against dermatophyte …
Butenafine hydrochloride: for the treatment of interdigital tinea pedis.
Syed TA, Maibach HI. Syed TA, et al. Expert Opin Pharmacother. 2000 Mar;1(3):467-73. doi: 10.1517/14656566.1.3.467. Expert Opin Pharmacother. 2000. PMID: 11249531 Review.
In controlled clinical trials when applied topically, butenafine appears to be well tolerated with a subjective mild burning sensation at the application site. There were no withdrawals from the study. Butenafine is sparingly soluble in water but readily soluble in …
In controlled clinical trials when applied topically, butenafine appears to be well tolerated with a subjective mild burning sensatio …
Repurposing Butenafine as An Oral Nanomedicine for Visceral Leishmaniasis.
Bezerra-Souza A, Fernandez-Garcia R, Rodrigues GF, Bolas-Fernandez F, Dalastra Laurenti M, Passero LF, Lalatsa A, Serrano DR. Bezerra-Souza A, et al. Pharmaceutics. 2019 Jul 20;11(7):353. doi: 10.3390/pharmaceutics11070353. Pharmaceutics. 2019. PMID: 31330776 Free PMC article.
Available treatments are not well tolerated due to severe adverse effects, need for parenteral administration and patient hospitalisation, and long duration of expensive treatments. ...In this work, we provide proof of concept studies of butenafine and but …
Available treatments are not well tolerated due to severe adverse effects, need for parenteral administration and patient hosp …
Formulation and evaluation of butenafine loaded PLGA-nanoparticulate laden chitosan nano gel.
Alshehri S, Imam SS. Alshehri S, et al. Drug Deliv. 2021 Dec;28(1):2348-2360. doi: 10.1080/10717544.2021.1995078. Drug Deliv. 2021. PMID: 34747275 Free PMC article.
The present research work is designed to prepare and optimize butenafine (BT) loaded poly lactic co glycolic acid (PLGA) nanoparticles (BT-NPs). BT-NPs were prepared by emulsification probe sonication method using PLGA (A), PVA (B) as polymer and stabilizer, respectively. …
The present research work is designed to prepare and optimize butenafine (BT) loaded poly lactic co glycolic acid (PLGA) nanoparticle …
Butenafine hydrochloride (Mentax) cream for the treatment of hyperkeratotic type tinea pedis and its transfer into the horny layer, with or without concomitant application of 20% urea ointment (Keratinamin).
Tanuma H, Doi M, Ohta Y, Abe M, Kume H, Mukai H, Katsuoka K. Tanuma H, et al. Mycoses. 2001;44(7-8):287-99. doi: 10.1046/j.0933-7407.2001.00653.x. Mycoses. 2001. PMID: 11714064
Forty-five patients were divided into two groups: group I, 23 patients, treated with butenafine hydrochloride (Mentax) cream alone, and group II, 22 patients, treated with butenafine hydrochloride and 20% urea ointment (Keratinamin) to evaluate the usefulness of the …
Forty-five patients were divided into two groups: group I, 23 patients, treated with butenafine hydrochloride (Mentax) cream alone, a …
One-week therapy with twice-daily butenafine 1% cream versus vehicle in the treatment of tinea pedis: a multicenter, double-blind trial.
Savin R, De Villez RL, Elewski B, Hong S, Jones T, Lowe N, Lucky A, Reyes B, Stewart D, Willis I. Savin R, et al. J Am Acad Dermatol. 1997 Feb;36(2 Pt 1):S15-9. doi: 10.1016/s0190-9622(97)70317-7. J Am Acad Dermatol. 1997. PMID: 9039200 Clinical Trial.
Adverse events to treatment occurred in less than 1% of patients treated with butenafine and 2% of patients who applied vehicle. CONCLUSION: Butenafine applied twice daily for 1 week is highly effective in treating interdigital tinea pedis....
Adverse events to treatment occurred in less than 1% of patients treated with butenafine and 2% of patients who applied vehicl …
Treatment of interdigital tinea pedis with a 4-week once-daily regimen of butenafine hydrochloride 1% cream.
Tschen E, Elewski B, Gorsulowsky DC, Pariser DM. Tschen E, et al. J Am Acad Dermatol. 1997 Feb;36(2 Pt 1):S9-14. doi: 10.1016/s0190-9622(97)70316-5. J Am Acad Dermatol. 1997. PMID: 9039199 Clinical Trial.
Results reported here are from one of the first major North American butenafine clinical trials. OBJECTIVE: We evaluated butenafine in the treatment of tinea pedis in a controlled, randomized, double-blind trial. ...RESULTS: Significantly more patients using bute …
Results reported here are from one of the first major North American butenafine clinical trials. OBJECTIVE: We evaluated butenafin …
The antifungal agent butenafine manifests anti-inflammatory activity in vivo.
Nahm WK, Orengo I, Rosen T. Nahm WK, et al. J Am Acad Dermatol. 1999 Aug;41(2 Pt 1):203-6. doi: 10.1016/s0190-9622(99)70049-6. J Am Acad Dermatol. 1999. PMID: 10426889 Clinical Trial.
Although several studies have demonstrated excellent antimycotic efficacy, none has addressed anti-inflammatory properties associated with butenafine. OBJECTIVE: This study was designed to determine whether butenafine, a benzylamine antifungal, expresses anti-inflam …
Although several studies have demonstrated excellent antimycotic efficacy, none has addressed anti-inflammatory properties associated with …
18 results